Advancing Immuno-Oncology Programs

Human Immuno-Oncology Program

Candidate

Indication

Preclinical Proof of Concept

Lead Candidate Optimization

IND

Enabling

Phase 1

Upcoming Goals

MIE-101

Multiple solid tumors

Completed or ongoing

Planned

GMP manufacturing, toxicology studies;

Preparation for IND filing or equivalent

CPMV.png

Phase 1 Objectives

  • Evaluate ascending dose safety and tolerability

  • Assess immune activation relationship to dose level

  • Measure anti-tumor responses,abscopal effects, and durability of responses

Veterinary Immuno-Oncology Program

To Learn more about our lead veterinary oncology treatment candidate, MIE-201, and our plans for its advancement into canine efficacy and safety field studies, please visit the Mosaic ImmunoEngineering Inc. Animal Health Website